By Jaime Llinares Taboada

AstraZeneca PLC said Thursday that Imfinzi combined with chemotherapy significantly improved pathologic complete response in patients with resectable lung cancer.

The pharmaceutical company reported positive results from an interim analysis of Phase III trials, as the treatment also caused a significant improvement in major pathologic response.

The trial will continue as planned to assess the additional primary endpoint of event-free survival.

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

(END) Dow Jones Newswires

June 30, 2022 02:28 ET (06:28 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Astrazeneca
Astrazeneca (LSE:AZN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Astrazeneca